Yonsei Med J.  2009 Oct;50(5):697-703. 10.3349/ymj.2009.50.5.697.

Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication

• Huh JW
• Park YA
• Lee KY
• Sohn SK

• KMID: 1103825
• DOI: http://doi.org/10.3349/ymj.2009.50.5.697

Abstract

PURPOSE
Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer. This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer. MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA. We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls. RESULTS: Interpretable results were available for 85.5% (118/138) of patients. The mean coefficient of variation for triplicate ATP measurements was 9.2%. The highest CDR was observed in irinotecan (34.0%) and the lowest CDR in etoposide (21.0%). Paclitaxel had the broadest range of CDR (0-86.7%) and 5-FU had the narrowest range of CDR (0-56.8%). The overall highest responsiveness was seen most prevalently in irinotecan (24.7%, 23/93 patients). Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma. CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.

Keyword

Adenosine triphosphate; chemotherapy response assay; colorectal cancer

MeSH Terms

Adenocarcinoma/*drug therapy
Adenosine Triphosphate/*metabolism
Adult
Aged
Aged, 80 and over
Antineoplastic Agents/*pharmacology/therapeutic use
Colorectal Neoplasms/*drug therapy
Drug Screening Assays, Antitumor/*methods
Female
Humans
Individualized Medicine
Male
Middle Aged
Tumor Cells, Cultured

Figure

• 

  Fig. 1 Mean value of CSI according to the histology (n = 73). Irinotecan had the greatest responsiveness in patients with well differenatiated (WD, n = 7) and moderately differentiated carcinoma (MD, n = 54), while paclitaxel had the greatest responsiveness in those with poorly differentiated and mucinous carcinoma (PD/MU, n = 12). However, there was no statistically significant correlation between responsiveness and histology (p = 0.144). CSI, Chemosensitivity Index.

Reference

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

2. Goldberg RM, Fleming TR, Tangen CM, Moertel CG, Macdonald JS, Haller DG, et al. Eastern Cooperative Oncology Group. the North Central Center Treatment Gtoup. the Southwest Oncology Group. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med. 1998. 129:27–35.

3. Liefers GJ, Tollenaar RA. Cancer genetics and their application to individualised medicine. Eur J Cancer. 2002. 38:872–879.

4. Cortazar P, Johnson BE. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol. 1999. 17:1625–1631.

5. Bogden AE, Griffin W, Reich SD, Costanza ME, Cobb WR. Predictive testing with the subrenal capsule assay. Cancer Treat Rev. 1984. 11:Suppl A. 113–124.

6. Rozencweig M, Hofmann V, Sanders C, Rombaut W, Früh U, Martz G. In vitro growth of human malignancies in a cloning assay. Recent Results Cancer Res. 1984. 94:1–7.

7. Tanigawa N, Kern DH, Hikasa Y, Morton DL. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res. 1982. 42:2159–2164.

8. Yamaue H, Tanimura H, Tsunoda T, Tani M, Iwahashi M, Noguchi K, et al. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer. 1991. 27:1258–1263.

9. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A. 1987. 84:5029–5033.

10. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol. 1988. 31:191–204.

11. Petty RD, Sutherland LA, Hunter EM, Cree IA. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin. 1995. 10:29–34.

12. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, et al. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs. 1999. 10:437–444.

13. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996. 7:630–635.

14. Kawamura H, Ikeda K, Takiyama I, Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer. 1997. 33:960–966.

15. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol. 2000. 77:258–263.

16. Kang SM, Park MS, Chang J, Kim SK, Kim H, Shin DH, et al. A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res Treat. 2005. 37:223–227.

17. Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA. Portsmouth Colorectal Cancer Multidisciplinary Team. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anticancer Drugs. 2003. 14:369–375.

18. Huh JW, Park YA, Sohn SK, Choi SH. In-vitro chemosensitivity test for colorectal cancer using an adenosine-triphosphate-based chemotherapy response assay (ATP-CRA). J Korean Soc Coloproctol. 2007. 23:172–179.

19. Huh JW, Park YA, Jung EJ, Lee KY, Kwon JE, Sohn SK. Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci. 2008. 23:916–919.

20. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep. 1986. 70:1283–1295.

21. Bird MC, Bosanquet AG, Gilby ED. In vitro determination of tumour chemosensitivity in haematological malignancies. Hematol Oncol. 1985. 3:1–10.

22. Nakahara T, Sakaeda T, Nakamura T, Tamura T, Nishioka C, Aoyama N, et al. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res. 2004. 21:406–412.

23. Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle. 2006. 5:818–823.

24. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995. 1:305–311.

25. Maehara Y, Kusumoto H, Kusumoto T, Anai H, Sugimachi K. Tumor tissue is more sensitive to mitomycin C, carboquone, and aclacinomycin A than is adjacent normal tissue in vitro. J Surg Oncol. 1989. 40:4–7.

26. Reinhold U, Tilgen W. Chemosensitivity testing in oncology. 2003. Heidelberg: Springer-Verlag;108–145.

27. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. In vitro chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol. 2006. 11:449–453.

28. Iwahashi M, Nakamori M, Nakamura M, Noguchi K, Ueda K, Nakatani Y, et al. Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer. Anticancer Res. 2005. 25:3453–3459.

29. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol. 2004. 22:3618–3630.

30. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004. 22:3631–3638.

31. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999. 79:1487–1493.

32. Ng TY, Ngan HY, Cheng DK, Wong LC. Clinical applicability of the ATP cell viability assay as a predictor of chemoresponce in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol. 2000. 76:405–408.

33. Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, et al. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer. 2007. 109:1829–1835.

34. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004. 22:23–30.

35. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004. 22:229–237.